Frédéric E Lecouvet1, Dimitar Boyadzhiev2, Laurence Collette3, Maude Berckmans4, Nicolas Michoux2, Perrine Triqueneaux2, Vassiliki Pasoglou2, François Jamar4, Marie-Christiane Vekemans5. 1. Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), Avenue Hippocrate, 10/2942, B-1200, Brussels, Belgium. frederic.lecouvet@uclouvain.be. 2. Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), Avenue Hippocrate, 10/2942, B-1200, Brussels, Belgium. 3. EORTC, Statistic Unit, EORTC Headquarters, Brussels, Belgium. 4. Department of Nuclear Medicine, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium. 5. Department of Haematology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium.
Abstract
PURPOSE: To compare the diagnostic performance of MRI and 18F-FDG-PET/CT in detecting bone marrow involvement (BMI) in patients with multiple myeloma (MM). MATERIALS AND METHODS: This retrospective study was approved by our Institutional Review Board. Two radiologists and two nuclear medicine specialists independently and blindly reviewed 84 pairs of MRI and PET/CT scans obtained in 73 MM patients. Readers assessed the presence and patterns of BMI. The best valuable comparator (BVC) for BMI was established by a panel review of all baseline and follow-up imaging, and biological and pathological information. Intra- and inter-reader agreement and correlation between MRI and PET/CT were assessed using the prevalence-adjusted bias-adjusted kappa (k) coefficient. Diagnostic performance of MRI and PET/CT in detecting BMI was evaluated from ROC characteristics. Association between imaging and biological, pathological, and clinical findings was assessed using Wilcoxon rank-sum and chi-square tests. RESULTS: Intra- and inter-reader agreement was very good for MRI (k = 0.90 [0.81; 1.00] and 0.88 [0.78; 0.98]). Intra- and inter-reader agreement was good for PET/CT (k = 0.80 [0.69; 0.91] and 0.71 [0.56; 0.86]). The sensitivity of MRI to detect BMI (97% [90%; 100%]) was significantly superior to that of PET/CT (76% [64%; 85%]) (p < 0.001). The specificity of MRI (86% [57%; 98%]) was lower than that of PET/CT (93% [66%; 100%]), without reaching statistical significance (p = 0.32). There was a strong correlation between decisions regarding patient management and PET/CT findings (p < 0.001). CONCLUSION: MRI is significantly more sensitive than PET/CT to detect BMI in MM. Patient management is more strongly correlated with PET/CT findings. KEY POINTS: • MRI and PET/CT have very close diagnostic value for the detection of bone marrow involvement in multiple myeloma. • MRI has a significantly higher sensitivity and better reproducibility. • PET/CT findings appear to have a higher impact on clinical decisions.
PURPOSE: To compare the diagnostic performance of MRI and 18F-FDG-PET/CT in detecting bone marrow involvement (BMI) in patients with multiple myeloma (MM). MATERIALS AND METHODS: This retrospective study was approved by our Institutional Review Board. Two radiologists and two nuclear medicine specialists independently and blindly reviewed 84 pairs of MRI and PET/CT scans obtained in 73 MMpatients. Readers assessed the presence and patterns of BMI. The best valuable comparator (BVC) for BMI was established by a panel review of all baseline and follow-up imaging, and biological and pathological information. Intra- and inter-reader agreement and correlation between MRI and PET/CT were assessed using the prevalence-adjusted bias-adjusted kappa (k) coefficient. Diagnostic performance of MRI and PET/CT in detecting BMI was evaluated from ROC characteristics. Association between imaging and biological, pathological, and clinical findings was assessed using Wilcoxon rank-sum and chi-square tests. RESULTS: Intra- and inter-reader agreement was very good for MRI (k = 0.90 [0.81; 1.00] and 0.88 [0.78; 0.98]). Intra- and inter-reader agreement was good for PET/CT (k = 0.80 [0.69; 0.91] and 0.71 [0.56; 0.86]). The sensitivity of MRI to detect BMI (97% [90%; 100%]) was significantly superior to that of PET/CT (76% [64%; 85%]) (p < 0.001). The specificity of MRI (86% [57%; 98%]) was lower than that of PET/CT (93% [66%; 100%]), without reaching statistical significance (p = 0.32). There was a strong correlation between decisions regarding patient management and PET/CT findings (p < 0.001). CONCLUSION: MRI is significantly more sensitive than PET/CT to detect BMI in MM. Patient management is more strongly correlated with PET/CT findings. KEY POINTS: • MRI and PET/CT have very close diagnostic value for the detection of bone marrow involvement in multiple myeloma. • MRI has a significantly higher sensitivity and better reproducibility. • PET/CT findings appear to have a higher impact on clinical decisions.
Entities:
Keywords:
Bone marrow; Magnetic resonance imaging; Multiple myeloma; Neoplasms; Positron-emission tomography
Authors: Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt Journal: J Clin Oncol Date: 2010-02-22 Impact factor: 44.544
Authors: Richard J Breyer; Michael E Mulligan; Stacy E Smith; Bruce R Line; Ashraf Z Badros Journal: Skeletal Radiol Date: 2006-06-07 Impact factor: 2.199
Authors: Shaji K Kumar; Vincent Rajkumar; Robert A Kyle; Mark van Duin; Pieter Sonneveld; María-Victoria Mateos; Francesca Gay; Kenneth C Anderson Journal: Nat Rev Dis Primers Date: 2017-07-20 Impact factor: 52.329
Authors: S L Giles; N M deSouza; D J Collins; V A Morgan; S West; F E Davies; G J Morgan; C Messiou Journal: Clin Radiol Date: 2015-03-19 Impact factor: 2.350
Authors: Olwen Westerland; Ashik Amlani; Christian Kelly-Morland; Michal Fraczek; Katherine Bailey; Mary Gleeson; Inas El-Najjar; Matthew Streetly; Paul Bassett; Gary J R Cook; Vicky Goh Journal: Eur J Nucl Med Mol Imaging Date: 2021-01-19 Impact factor: 9.236
Authors: Frederic E Lecouvet; Marie-Christiane Vekemans; Thomas Van Den Berghe; Koenraad Verstraete; Thomas Kirchgesner; Souad Acid; Jacques Malghem; Joris Wuts; Jens Hillengass; Vincent Vandecaveye; François Jamar; Olivier Gheysens; Bruno C Vande Berg Journal: Skeletal Radiol Date: 2021-08-07 Impact factor: 2.199